Meta-Analysis:
Metabolic syndrome and pancreatic cancer risk: a systematic review and metaanalysis
Metrics: PDF 707 views | Full Text 1612 views
Liuping You1,*, Li Ning2,*, Weimin Xie2,*, Jinghe Lang2 and Yuenan Huang1
1Department of General Surgery, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
2Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
*These authors contributed equally to this work
Correspondence to:
Yuenan Huang, email: [email protected]
Keywords: pancreatic cancer; metabolic syndrome; risk; meta-analysis
Received: May 09, 2017 Accepted: December 06, 2017 Published: January 12, 2018
ABSTRACT
The aim of this study was to evaluate the association between metabolic syndrome and pancreatic cancer risk by conducting a meta-analysis. We searched the databases of Embase, PubMed, and Cochrane Central Register of Controlled Trials from inception to March 2017. We also searched clinical trial registries for ongoing trials. Studies investigating the association between metabolic syndrome and pancreatic cancer risk were included. Pooled relative risk (RR) was calculated using either a random-effects or a fixed-effects model. A total of 4 studies involving 622,694 participants were identified. The pooled data showed that metabolic syndrome was associated with a statistically significant 40% increase in pancreatic cancer risk (RR, 1.40; 95% CI, 1.06 to 1.86) with significant heterogeneity (I2 =78.1%). A somewhat stronger association was observed in women (RR, 1.58; 95% CI, 1.36 to 1.84; I2 = 0.0%) than in men (RR, 1.25; 95% CI, 0.77 to 2.04; I2 =71.7%). Our findings support that patients with metabolic syndrome carry an increased risk for developing pancreatic cancer.